鼻咽癌IMRT再计划的研究进展

doi:10.3760/cma.j.issn.1004-4221.2018.03.017

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Intensity-modulated radiotherapy (IMRT) is the first-line treatment for nasopharyngeal carcinoma currently. Previous studies have shown that regression of primary tumor and metastatic lymph nodes or a decrease in body weight causes the contour of normal organs and head-and-neck to shrink during the course of radiotherapy, which may lead to underdose in primary tumor and overdose in organs at risk (OARs) and then adversely affect treatment outcomes. Replanning during the course of radiotherapy can maintain the dose to target volume and reduce the exposure of OARs, which improves outcomes in some patients. For replanning during the course of IMRT, however, the advantages have not been widely recognized and there is still a long way to go before widely accepted timing and frequency of replanning are set up. Further studies are needed to figure out how to identify patients appropriate for plan modification.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Shen Qun
	Luo Li
	Liu Feng
	Xi Xuping

Key words： Nasopharyngeal neoplasm/intensity-modulated radiotherapy Replanning

Received: 29 March 2017

Fund:South Province Health and Family Planning Commission Project (C2014-37);China Cancer Foundation Beijing Hope Marathon Special Fund (LC2016W05);Hunan Provincial Science and Technology Department (2016jj6088);Hunan Province Health and Family Planning Commission Project (B2016048)

Corresponding Authors: Xi Xuping,Email:xixuping@163.com

Cite this article:

Shen Qun,Luo Li,Liu Feng et al. Research progress in replanning during intensity-modulated radiotherapy for nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(3): 312-315.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.03.017 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I3/312

[1] Yan D,Yan S,Wang Q,et al. Predictors for replanning in loco-regionally advanced nasopharyngeal carcinoma patients undergoing intensity-modulated radiation therapy:a prospective observational study[J].BMC Cancer,2013,13:548.DOI:10.1186/1471-2407-13-548.
[2] Yang H,Hu W,Wang W,et al. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2013,85(1):e47-54.DOI:10.1016/j.ijrobp.2012.09.033.
[3] Hansen EK,Bucci MK,Quivey JM,et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer[J].Int J Radiat Oncol Biol Phys,2006,64(2):355-62.DOI:10.1016/j.ijrobp.2005.07.957
[4] Zhao L,Wan Q,Zhou Y,et al. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma[J].Radiother Oncol,2011,98(1):23-27.DOI:10.1016/j.radonc.2010.10.009.
[5] Wu Q,Chi Y,Chen PY,et al. Adaptive replanning strategies accounting for shrinkage in head and neck IMRT[J].Int J Radiat Oncol Biol Phys,2009,75(3):924-932 DOI:10.1016/j.ijrobp.2009.04.047.
[6] Chen AM,Daly ME,Cui J,et al. Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning[J].Head Neck,2014,36(11):1541-1546.DOI:10.1002/hed.23477.
[7] Luo Y,Qin Y,Lang J,et al. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy[J].Clin Transl Oncol,2017,19(4):470-476.DOI:10.1007/s12094-016-1551-8.
[8] Yao WR,Xu SP,Liu B,et al. Replanning criteria and timing definition for parotid protection-based adaptive radiation therapy in nasopharyngeal carcinoma[J].Biomed Res Int,2015:476383.DOI:10.1155/2015/476383.
[9] Cheng HC,Wu VW,Ngan RK,et al. A prospective study on volumetric and dosimetric changes during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients[J].Radiother Oncol,2012,104(3):317-323.DOI:10.1016/j.radonc.2012.03.013.
[10] Chen C,Fei Z,Chen L,et al. Will weight loss cause significant dosimetric changes of target volumes and organs at risk in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy[J]? Med Dosim,2014,39(1):34-37.DOI:10.1016/j.meddos.2013.09.002.
[11] Chen C,Lin X,Pan J,et al. Is it necessary to repeat CT imaging and replanning during the course of intensity-modulated radiation therapy for locoregionally advanced nasopharyngeal carcinoma[J]? Jpn J Radiol,2013,31(9):593-599.DOI:10.1007/s11604-013-0225-5.
[12] Wang W,Yang H,Hu W,et al. Clinical study of the necessity of replanning before the 25^th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2010,77(2):617-621.DOI:10.1016/j.ijrobp.2009.08.036.
[13] Fung WW,Wu VW,Teo PM,et al. Developing an adaptive radiation therapy strategy for nasopharyngeal carcinoma[J].J Radiat Res,2014,55(2):293-304.DOI:10.1093/jrr/rrt103.
[14] Huang H,Lu H,Feng G,et al. Determining appropriate timing of adaptive radiation therapy for nasopharyngeal carcinoma during intensity-modulated radiation therapy[J].Radiat Oncol,2015,10(1):192.DOI:10.1186/s13014-015-0498-1.
[15] Yang H,Hu W,Ding W,et al. Changes of the transverse diameter and volume and dosimetry before the 25^th fraction during the course of intensity-modulated radiation therapy (IMRT) for patients with nasopharyngeal carcinoma[J].Med Dosim,2012,37(2):225-229.DOI:10.1016/j.meddos.2011.08.003.
[16] Mayo C,Yorke E,Merchant TE,et al. Radiation associated brainstem injury[J].Int J Radiat Oncol Biol Phys,2010,76(3):S36-41.DOI:10.1016/j.ijrobp.2009.08.078.
[17] Kirkpatrick JP,van der Kogel AJ,et al. Radiation dose-volume effects in the spinal cord[J].Int J Radiat Oncol Biol Phys,2010,76(3):S42-49.DOI:10.1016/j.ijrobp.2009.04.095.
[18] Nishi T,Nishimura Y,Shibata T,et al. Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy (IMRT) scheme for head and neck cancer[J].Radiother Oncol,2013,106(1):85-99.DOI:10.1016/j.radonc.2012.11.005.
[19] Tribius S,Sommer J,Prosch C,et al. Xerostomia after radiotherapy. What matters—mean total dose or dose to each parotid gland[J]? Strahlenther Onkol,2013,189(1):216-222.DOI:10.1007/s00066-012-0257-2.
[20] Bhide SA,Davies M,Burke K,et al. Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer:a prospective observational study[J].Int J Radiat Oncol Biol Phys,2010,76(5):1360-1368.DOI:10.1016/j.ijrobp.2009.04.005.
[21] Brown E,Owen R,Harden F,et al. Predicting the need for adaptive radiotherapy in the head and neck cancer[J].Radiother Oncol,2015,116(1):57-63.DOI:10.1016/j.radonc.2015.06.025.
[22] Capelle L,Mackenzie M,Field C,et al. Adaptive radiotherapy using helical tomotherapy for head and neck cancers in definitive and postoperative settings:initial results[J].Clin Oncol (R Coll Radiol),2012,24(1):208-215.DOI:10.1016/j.clon.2011.11.005.
[23] Jin X,Hu W,Shang H,et al. CBCT-based volumetric and dosimetric variation evaluation of volumetric modulated arc radiotherapy in the treatment of nasopharyngeal cancer patients[J].Radiat Oncol,2013,8(2):279.DOI:10.1186/1748-717X-8-279.